GSC
PGNX

Ground Swell Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Ground Swell Capital’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$2K Buy
+474
New +$2.36K ﹤0.01% 1982

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ground Swell Capital's PGNX Position: Q3 2014 in Review

Ground Swell Capital opened a new position in Progenics Pharmaceuticals Inc (PGNX) in Q3 2014: 474 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1982 among its holdings.

78 funds tracked by Wall St. Rank hold PGNX as of Q3 2014.

  • Ground Swell Capital held 474 shares of Progenics Pharmaceuticals Inc worth $2K as of Q3 2014.
  • Progenics Pharmaceuticals Inc was a new Ground Swell Capital position in Q3 2014.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1982 holding.
  • 78 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.